Sensorineural Hearing Loss after Chemoradiotherapy with High-Dose Cisplatin in Patients with Head and Neck Cancer

Abstract

Objective To investigate sensorineural hearing loss in patients with head and neck cancer receiving chemoradiotherapy (CRT) with a standard regimen of high-dose cisplatin, focusing on the acute changes before and after CRT with high-dose cisplatin (CDDP).

Materials and Methods A total of, 135 cases of head and neck cancer treated with high-dose cisplatin-based CRT between 2014 and 2023 were included in this retrospective study. The hearing threshold shifts at each frequency before and after each CDDP dose were used as an indicator to assess hearing impairment.

Results The CRT-induced hearing threshold shift was greater at frequencies >4,000 Hz, with a threshold increment of ∼10 dB at 4,000 Hz and 20 dB at 8,000 Hz. The threshold after each course of CDDP was elevated at one week after CDDP administration, and the changes in the thresholds from one week after administration to just before the subsequent course were small. Total CDDP dose, radiation dose to the cochlea, and mean pretreatment hearing thresholds were identified as significant factors influencing the increase in hearing thresholds at 8,000 Hz.

Conclusion In patients with head and neck cancer receiving CRT with high-dose cisplatin, threshold increment was predominantly observed at frequencies >4,000 Hz, as previously reported. The threshold increment occurred immediately after CDDP administration, which might be relevant when considering the timing of future interventions.

Keywords

sensorineural hearing loss - chemoradiotherapy - high-dose cisplatin - head and neck cancer

Publikationsverlauf

Eingereicht: 20. August 2024

Angenommen: 13. November 2024

Artikel online veröffentlicht:
06. Februar 2025

• References

• 1 Pandav R, Yadav V, Bhagat S, Sharma DK. Ototoxicity in patients of advanced head and neck malignancies receiving chemoradiation versus radiation alone: comparative study. Indian J Otolaryngol Head Neck Surg 2022; 74 (Suppl. 03) 3927-3932
• 2 Morita I, Hosokawa S, Hiraide F, Inouye T. Cisplatin ototoxicity. Pract Otorhinolaryngol 1985; 78: 561-568
• 3 Laurell G, Engström B. The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hear Res 1989; 38 (1–2): 27-33
• 4 Theunissen EA, Bosma SC, Zuur CL. et al. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck 2015; 37 (02) 281-292
• 5 Zuur CL, Simis YJ, Lansdaal PE. et al. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 2007; 25 (24) 3759-3765
• 6 Chen WC, Jackson A, Budnick AS. et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006; 106 (04) 820-829
• 7 Chan SH, Ng WT, Kam KL. et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys 2009; 73 (05) 1335-1342
• 8 Schuette A, Lander DP, Kallogjeri D. et al. Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 2020; 146 (02) 106-112
• 9 Lee DS, Mahal RS, Tharakan T. et al. Hearing outcomes in a deintensification trial of adjuvant therapy for HPV-related oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2023; 168 (05) 1089-1096
• 10 Gamez ME, Blakaj DM, Bhateja P. et al. Audiological outcomes of weekly vs. triweekly cisplatin in head and neck cancer with cochlear-sparing intensity-modulated radiation therapy. Cancers (Basel) 2024; 16 (12) 2228
• 11 Kiyota N, Tahara M, Mizusawa J. et al; Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial. J Clin Oncol 2022; 40 (18) 1980-1990
• 12 Marks LB, Yorke ED, Jackson A. et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76 (suppl 3) S10-S19
• 13 Huang Y, Zhou H, An F. et al. The relevance of ototoxicity induced by radiotherapy. Radiat Oncol 2023; 18 (01) 95
• 14 Zuur CL, Simis YJ, Verkaik RS. et al. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol 2008; 89 (01) 38-43
• 15 National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Crtieria for Adverse Events (CTCAE), Version 5.0. pp13, 2017
• 16 American Speech-Language-Hearing Association (ASHA). Guidelines for the audiologic management of individuals recieving cochleotoxic drug therapy. ASHA 1994; 36: 1-19
• 17 Theunissen EA, Dreschler WA, Latenstein MN. et al. A new grading system for ototoxicity in adults. Ann Otol Rhinol Laryngol 2014; 123 (10) 711-718
• 18 Crundwell G, Gomersall P, Baguley DM. Ototoxicity (cochleotoxicity) classifications: a review. Int J Audiol 2016; 55 (02) 65-74
• 19 Shetty S, Bhandary SK, Bhat V, Aroor R, Shetty J, Dattatreya T. Role of otoacoustic emission in early detection of cisplatin induced ototoxicity. Indian J Otolaryngol Head Neck Surg 2022; 74 (Suppl. 01) 164-169
• 20 Chan SL, Ng LS, Goh X. et al. Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. Head Neck 2018; 40 (07) 1425-1433
• 21 Hong DZ, Ong TCC, Timbadia DP. et al. Systematic review and meta-analysis of the influence of genetic variation on ototoxicity in platinum-based chemotherapy. Otolaryngol Head Neck Surg 2023; 168 (06) 1324-1337